VigilAI- Agentic AI Platform for Autonomous Pharmacovigilance
Brillio · Intelligence & Research
Certification per AWS Marketplace.
Evidence tier Source Confirmed · 4 captures on record
What the publisher says
As described on AWS Marketplace.
VigilAI is an agentic AI–powered pharmacovigilance platform that transforms adverse event management from manual, sequential workflows into autonomous, real-time safety intelligence. By orchestrating specialized AI agents across the end-to-end case lifecycle, VigilAI automates intake, validation, causality assessment and regulatory reporting, delivering ICH E2B(R3)-compliant ICSRs in under 24 hours. With embedded human-in-the-loop oversight, full traceability and regulatory-grade compliance, VigilAI enables pharma organizations to scale safety operations, reduce costs and enhance patient risk detection.
The solution powered by AWS services is designed to enable Life Sciences organizations to transform pharmacovigilance through scalable, AI-driven safety operations and real-time intelligence.
Show the rest of the publisher’s description (20 more lines)
It leverages a robust AWS stack- EKS, ECR, API Gateway, Application Load Balancer, Bedrock, Kendra, and DynamoDB to deliver secure, containerized orchestration, intelligent search, LLM-driven reasoning with enterprise-grade compliance.
### Challenges:
Traditional safety operations are built on manual, fragmented, and sequential workflows that take 7–15 days per case and rely heavily on human intervention across intake, coding, medical review, and submission.
At the same time, the landscape is rapidly evolving:
- 30–50% annual growth in AE volumes driven by digital channels, patient programs and real-world data.
- Increasing reliance on unstructured data sources such as EHRs, literature and social media.
- Rising regulatory expectations for data completeness, traceability and timeliness.
- Growing complexity of therapies, including biologics and gene therapies, making causality assessment more challenging.
Incremental automation approaches (RPA, rule-based tools) have delivered limited gains, as they address isolated tasks rather than the end-to-end workflow. As a result, pharmacovigilance functions face rising costs, operational bottlenecks, delayed reporting risks, and missed safety signals.
This creates a clear need to transition from reactive case processing to proactive, AI-driven safety intelligence.
### The Brillio Solution:
The solution deploys a coordinated system of specialized AI agents that mimic key pharmacovigilance roles and collaborate to process adverse events end-to-end.
Each AI agent contributes domain-specific intelligence:
- Intake Manager captures and structures adverse event signals from any source.
- Subject Historian builds a comprehensive patient safety profile using historical data.
- Drug Detective evaluates drug exposure, interactions, and causality.
- Infection Analyst identifies opportunistic infection risks and correlations.
- Severity Classifier determines seriousness, expectedness, and reporting priority.
These agents operate within a unified orchestration layer ingesting data from multiple sources (EHRs, literature, social media, call center interactions) enabling parallel processing and generating regulatory submission-ready ICSRs aligned with ICH E2B(R3) standards.
A critical differentiator is the Human-in-the-Loop (HITL) model, where all AI-driven outputs are reviewed and validated by safety professionals. Combined with full decision traceability and auditability, the solution ensures compliance with global regulatory requirements, including 21 CFR Part 11, GAMP 5, and emerging AI governance frameworks.
Highlights
Highlighted by the publisher on AWS Marketplace.
Autonomous End-to-End Case Processing: A coordinated multi-agent system orchestrating the full case lifecycle reducing processing timelines from 7–15 days to under 24 hours.
Real-Time Safety Intelligence: Enables continuous signal detection and contextual analysis transforming retrospective reporting into real-time intelligence.
Scalable, Compliant Operating Model: With embedded human oversight, full traceability, and regulatory alignment, VigilAI delivers 70–80% automation, 40–60% cost reduction and scalability without linear headcount growth.
Agent build and provenance
See the full provenance
The layer-by-layer build, the evidence behind each claim, the risk basis and the cross-marketplace links are open to any account. Some rows are disclosed, some the source leaves Unknown; a free account shows you which.
Compliance
- FedRAMPConfirmedNot listed90%, registry-checkedNo FedRAMP Marketplace entry matched this vendor's domain, checked 2026-08-27registry recordas observed 2026-08-27
Confirmed means matched to a public authoritative registry. Claimed means the vendor or its listing states it, not yet cross-checked. A framework not shown was not found in any source we hold, which is not evidence against it. Not listed means a scoped registry check found no match for this vendor's domain: a No is a scoped registry check, not a compliance judgment. Confidence bands: 95% domain-verified, 90% registry-checked, 80% self-attested, 70% weak signal. Self-attested items marked “vendor's site” are gathered from the vendor's own website and are not verified by us.
Vendor
External enrichment · as of 2026-08-29
Sources
Publisher resources
1 linkLinked repositories
Unknown means this listing does not publish a repository. It is not a statement that the code is closed, and a linked repository is not a claim that the publisher wrote it: the registry computes that relationship privately and does not publish it.
Evidence risk is the share of the build you cannot see before you deploy, not a security rating. Sign in to see the layer-by-layer basis for this band.

